Familial Hypercholesterolemia: Do HDL Play a Role?

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2021 Aug 6

PMID 34356876

Citations 12

Authors

Juan Pedro-Botet

Elisenda Climent

David Benaiges

Affiliations

Soon will be listed here.

Abstract

Cardiovascular disease (CVD) in heterozygous familial hypercholesterolemia (HeFH), the most frequent monogenic disorder of human metabolism, is largely driven by low-density lipoprotein (LDL) cholesterol concentrations. Since the CVD rate differs considerably in this population, beyond the lifetime LDL cholesterol vascular accumulation, other classical risk factors are involved in the high cardiovascular risk of HeFH. Among other lipoprotein disturbances, alterations in the phenotype and functionality of high-density lipoproteins (HDL) have been described in HeFH patients, contributing to the presence and severity of CVD. In fact, HDL are the first defensive barrier against the burden of high LDL cholesterol levels owing to their contribution to reverse cholesterol transport as well as their antioxidant and anti-inflammatory properties, among others. In this context, the present narrative review aimed to focus on quantitative and qualitative abnormalities in HDL particles in HeFH, encompassing metabolic, genetic and epigenetic aspects.

Citing Articles

Blood Lipid Polygenic Risk Score Development and Application for Atherosclerosis Ultrasound Parameters.

Zaicenoka M, Ershova A, Kiseleva A, Blokhina A, Kutsenko V, Sotnikova E Biomedicines. 2025; 12(12.

PMID: 39767705 PMC: 11673070. DOI: 10.3390/biomedicines12122798.

Clinical and biochemical features of atherogenic hyperlipidemias with different genetic basis: A comprehensive comparative study.

Blokhina A, Ershova A, Kiseleva A, Sotnikova E, Zharikova A, Zaicenoka M PLoS One. 2024; 19(12):e0315693.

PMID: 39705280 PMC: 11661581. DOI: 10.1371/journal.pone.0315693.

Familial Hypercholesterolemia: Pitfalls and Challenges in Diagnosis and Treatment.

Arnold N, Koenig W Rev Cardiovasc Med. 2024; 24(8):236.

PMID: 39076699 PMC: 11266816. DOI: 10.31083/j.rcm2408236.

Resilient Older Subjects with Heterozygous Familial Hypercholesterolemia, Baseline Differences and Associated Factors.

Climent E, Gonzalez-Guerrero A, Marco-Benedi V, Garcia-Andreu M, Mediavilla-Garcia J, Suarez-Tembra M Int J Mol Sci. 2024; 25(9).

PMID: 38732050 PMC: 11084769. DOI: 10.3390/ijms25094831.

Cholesterol efflux capacity is increased in subjects with familial hypercholesterolemia in a retrospective case-control study.

Sanz J, DAmuri A, Sergi D, Angelini S, Fortunato V, Favari E Sci Rep. 2023; 13(1):8415.

PMID: 37225774 PMC: 10209072. DOI: 10.1038/s41598-023-35357-4.

References

Bahrami A, Liberale L, Reiner Z, Carbone F, Montecucco F, Sahebkar A . Inflammatory Biomarkers for Cardiovascular Risk Stratification in Familial Hypercholesterolemia. Rev Physiol Biochem Pharmacol. 2020; 177:25-52. DOI: 10.1007/112_2020_26. View

Ferri N, Corsini A, Macchi C, Magni P, Ruscica M . Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence. Transl Res. 2015; 173:19-29. DOI: 10.1016/j.trsl.2015.10.004. View

Scicali R, Di Pino A, Pavanello C, Ossoli A, Strazzella A, Alberti A . Analysis of HDL-microRNA panel in heterozygous familial hypercholesterolemia subjects with LDL receptor null or defective mutation. Sci Rep. 2020; 9(1):20354. PMC: 6937253. DOI: 10.1038/s41598-019-56857-2. View

Guay S, Brisson D, Lamarche B, Gaudet D, Bouchard L . Epipolymorphisms within lipoprotein genes contribute independently to plasma lipid levels in familial hypercholesterolemia. Epigenetics. 2014; 9(5):718-29. PMC: 4063831. DOI: 10.4161/epi.27981. View

Swertfeger D, Rebholz S, Li H, Shah A, Davidson W, Lu L . Feasibility of a plasma bioassay to assess oxidative protection of low-density lipoproteins by high-density lipoproteins. J Clin Lipidol. 2018; 12(6):1539-1548. PMC: 6437770. DOI: 10.1016/j.jacl.2018.08.007. View

Lakoski S, Lagace T, Cohen J, Horton J, Hobbs H . Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab. 2009; 94(7):2537-43. PMC: 2708952. DOI: 10.1210/jc.2009-0141. View

Eichler E, Flint J, Gibson G, Kong A, Leal S, Moore J . Missing heritability and strategies for finding the underlying causes of complex disease. Nat Rev Genet. 2010; 11(6):446-50. PMC: 2942068. DOI: 10.1038/nrg2809. View

Junyent M, Cofan M, Nunez I, Gilabert R, Zambon D, Ros E . Influence of HDL cholesterol on preclinical carotid atherosclerosis in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2006; 26(5):1107-13. DOI: 10.1161/01.ATV.0000218507.95149.42. View

Jansen A, van Aalst-Cohen E, Tanck M, Trip M, Lansberg P, Liem A . The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med. 2004; 256(6):482-90. DOI: 10.1111/j.1365-2796.2004.01405.x. View

10.

Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray K, Thompson A . Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009; 302(18):1993-2000. PMC: 3284229. DOI: 10.1001/jama.2009.1619. View

11.

Guay S, Voisin G, Brisson D, Munger J, Lamarche B, Gaudet D . Epigenome-wide analysis in familial hypercholesterolemia identified new loci associated with high-density lipoprotein cholesterol concentration. Epigenomics. 2012; 4(6):623-39. DOI: 10.2217/epi.12.62. View

12.

Qian L, Gao Y, Zhang Y, Chu M, Yao J, Xu D . Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials. Sci Rep. 2017; 7(1):238. PMC: 5428249. DOI: 10.1038/s41598-017-00316-3. View

13.

Cedo L, Metso J, Santos D, Garcia-Leon A, Plana N, Sabate-Soler S . LDL Receptor Regulates the Reverse Transport of Macrophage-Derived Unesterified Cholesterol via Concerted Action of the HDL-LDL Axis: Insight From Mouse Models. Circ Res. 2020; 127(6):778-792. DOI: 10.1161/CIRCRESAHA.119.316424. View

14.

Humphries S, Cooper J, Seed M, Capps N, Durrington P, Jones B . Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register. Atherosclerosis. 2018; 274:41-46. PMC: 6013645. DOI: 10.1016/j.atherosclerosis.2018.04.040. View

15.

Hussein H, Saheb S, Couturier M, Atassi M, Orsoni A, Carrie A . Small, dense high-density lipoprotein 3 particles exhibit defective antioxidative and anti-inflammatory function in familial hypercholesterolemia: Partial correction by low-density lipoprotein apheresis. J Clin Lipidol. 2016; 10(1):124-33. DOI: 10.1016/j.jacl.2015.10.006. View

16.

Frenais R, Ouguerram K, Maugeais C, Marchini J, Benlian P, Bard J . Apolipoprotein A-I kinetics in heterozygous familial hypercholesterolemia: a stable isotope study. J Lipid Res. 1999; 40(8):1506-11. View

17.

Raal F, Stein E, Dufour R, Turner T, Civeira F, Burgess L . PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2014; 385(9965):331-40. DOI: 10.1016/S0140-6736(14)61399-4. View

18.

Khoury E, Brisson D, Roy N, Tremblay G, Gaudet D . Identifying Markers of Cardiovascular Event-Free Survival in Familial Hypercholesterolemia. J Clin Med. 2020; 10(1). PMC: 7794820. DOI: 10.3390/jcm10010064. View

19.

Gibson J, Goldberg R, Rubinstein A, Ginsberg H, Brown W, Baker S . Plasma lipoprotein distribution of apolipoprotein E in familial hypercholesterolemia. Arteriosclerosis. 1987; 7(4):401-7. DOI: 10.1161/01.atv.7.4.401. View

20.

Rodriguez A, Trigatti B, Mineo C, Knaack D, Wilkins J, Sahoo D . Proceedings of the Ninth HDL (High-Density Lipoprotein) Workshop: Focus on Cardiovascular Disease. Arterioscler Thromb Vasc Biol. 2019; 39(12):2457-2467. PMC: 6937204. DOI: 10.1161/ATVBAHA.119.313340. View